Clinical Trial Update: A Phase Ib Study of RC1416 Injection [Phase 1]

View source ↗

Summary

Phase Ib study of RC1416 Injection for moderate to severe asthma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asthma

Drugs mentioned

• RC1416 Injection

Snippet

Sponsor: Nanjing RegeneCore Biotech Co., Ltd. | Conditions: Moderate to Severe Asthma | Phase 1 | Status: COMPLETED